GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » EV-to-FCF

MindBio Therapeutics (XCNQ:MBIO) EV-to-FCF : -12.10 (As of Jun. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MindBio Therapeutics's Enterprise Value is C$10.39 Mil. MindBio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.86 Mil. Therefore, MindBio Therapeutics's EV-to-FCF for today is -12.10.

The historical rank and industry rank for MindBio Therapeutics's EV-to-FCF or its related term are showing as below:

XCNQ:MBIO' s EV-to-FCF Range Over the Past 10 Years
Min: -15   Med: -10.1   Max: -5.18
Current: -12.09

During the past 3 years, the highest EV-to-FCF of MindBio Therapeutics was -5.18. The lowest was -15.00. And the median was -10.10.

XCNQ:MBIO's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.86 vs XCNQ:MBIO: -12.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-14), MindBio Therapeutics's stock price is C$0.045. MindBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.023. Therefore, MindBio Therapeutics's PE Ratio for today is At Loss.


MindBio Therapeutics EV-to-FCF Historical Data

The historical data trend for MindBio Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics EV-to-FCF Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
EV-to-FCF
- - -6.80

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - -6.80 -7.47 -5.67 -13.45

Competitive Comparison of MindBio Therapeutics's EV-to-FCF

For the Biotechnology subindustry, MindBio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's EV-to-FCF falls into.



MindBio Therapeutics EV-to-FCF Calculation

MindBio Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.385/-0.858
=-12.10

MindBio Therapeutics's current Enterprise Value is C$10.39 Mil.
MindBio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MindBio Therapeutics  (XCNQ:MBIO) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MindBio Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.045/-0.023
=At Loss

MindBio Therapeutics's share price for today is C$0.045.
MindBio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


MindBio Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus